COVID-19 can result in cardiac complications including myocarditis, arterial and venous thromboembolism, and cardiomyopathy.
A presentation given at the Radiological Society of North America (RSNA) Annual Meeting on November 28th covered the cardiovascular imaging manifestations of COVID-19.
“SARS-CoV-2 is a novel coronavirus which primarily affects the respiratory system, but has also been shown to impact other systems, especially with the hypercoagulable state,” said Margaret Revzon, M.D., an associate professor of radiology and biomedical imaging at Yale School of Medicine, in New Haven, Conn. “The hypercoagulable state and resulted vascular complications are not uncommon in patients with COVID-19.”
COVID-19 can result in cardiac complications including myocarditis, arterial and venous thromboembolism, and cardiomyopathy. While ultrasound is the first imaging choice for these patients, computerized tomography (CT) can be selected, but clinicians must note that the COVID-19 patient is often in the prone position. Magnetic resonance imaging (MRI) can be used for complex cases. Dr. Revzon highlighted that awareness and recognition of imaging manifestations of COVID-19 induced thromboembolic complications will ensure optimal treatment for these patients.
Brian Burns Ghoshhajra, M.D., associate professor of radiology at Harvard medical School in Boston, Mass., said that “there is systematic inflammation, endothelial activation and direct myocardial effects of SARS-CoV-2.”
While cardiovascular imaging, including CT and MRI, play a key role, context and pre-test probably likely matter more than ever. Dr. Ghoshhajra suggested that radiology services should be optimized for cardiac imaging.
“COVID-19 doesn’t occur in a vacuum, so remember your basics and cast a wide diagnostic net of there is not an established COVID-19 diagnosis yet,” Dr. Ghoshhajra said.
There have also been infrequent emerging reports of myocarditis and myocardial injury in a minority of patients after COVID-19 vaccination.
Kate Hanneman, M.D., FRCPC, an associate professor in the department of medical imaging at Women's College Hospital in Toronto, Canada, explained that there are limited data on what cardiac imaging findings are expected in these patients. However, the pattern on imaging appears to be like myocarditis from other causes, but less extensive compared to other causes of myocarditis.
“The extent on imaging, based on the reports we have to date, appears to be relatively mild. So less extensive compared to some other causes of myocarditis,” Dr. Hanneman said.
For more coverage of RSNA 2021, click here.
FDA Grants Expanded 510(k) Clearance for Xenoview 3T MRI Chest Coil in GE HealthCare MRI Platforms
November 21st 2024Utilized in conjunction with hyperpolarized Xenon-129 for the assessment of lung ventilation, the chest coil can now be employed in the Signa Premier and Discovery MR750 3T MRI systems.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
November 18th 2024Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.